Arbutus to Participate at the 2018 B. Riley FBR Healthcare Conference

WARMINSTER, Pa., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation ABUS, an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia, Arbutus' Chief Scientific Officer, will participate in the Hepatitis B Functional Cure Panel at the B. Riley FBR Healthcare Conference on Tuesday, September 4, 2018 at 9:50 am – 10:50 am ET in New York.

About Arbutus

Arbutus Biopharma Corporation is a publicly-traded ABUS biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit www.arbutusbio.com.

Contact Information

Investors

Mark Murray

President and CEO

Phone: 604-419-3200

Email: ir@arbutusbio.com

Pam Murphy

Investor Relations Consultant

Phone: 604-419-3200

Email: ir@arbutusbio.com

Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CarePress ReleasesGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!